Latest Insider Transactions at Strongbridge Biopharma PLC (SBBP)
This section provides a real-time view of insider transactions for Strongbridge Biopharma PLC (SBBP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Strongbridge Biopharma plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Strongbridge Biopharma plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 05
2021
|
Cdk Associates, L.L.C. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
8,060,682
-100.0%
|
-
|
|
Oct 05
2021
|
Stephen J Long Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
117,793
-100.0%
|
-
|
|
Oct 05
2021
|
David N Gill Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
78,058
-100.0%
|
-
|
|
Oct 05
2021
|
Garheng Kong Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
63,993
-100.0%
|
-
|
|
Oct 05
2021
|
Jeffrey W Sherman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
64,258
-100.0%
|
-
|
|
Oct 05
2021
|
Marten Steen Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
64,151
-100.0%
|
-
|
|
Oct 05
2021
|
Hilde H Steineger Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
64,258
-100.0%
|
-
|
|
Oct 05
2021
|
John Johnson Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
610,092
-100.0%
|
-
|
|
Oct 05
2021
|
Fredric J. Cohen Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
160,408
-50.0%
|
-
|
|
Oct 05
2021
|
Richard S Kollender President and CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
234,229
-100.0%
|
-
|
|
Oct 05
2021
|
Scott L. Wilhoit Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
109,510
-100.0%
|
-
|
|
Oct 01
2021
|
David N Gill Director |
SELL
Payment of exercise price or tax liability
|
Direct |
17,763
-18.54%
|
$35,526
$2.06 P/Share
|
|
Oct 01
2021
|
Garheng Kong Director |
SELL
Payment of exercise price or tax liability
|
Direct |
17,763
-21.73%
|
$35,526
$2.06 P/Share
|
|
Oct 01
2021
|
Jeffrey W Sherman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
17,763
-21.66%
|
$35,526
$2.06 P/Share
|
|
Oct 01
2021
|
Hilde H Steineger Director |
SELL
Payment of exercise price or tax liability
|
Direct |
17,763
-21.66%
|
$35,526
$2.06 P/Share
|
|
Oct 01
2021
|
John Johnson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
334,868
-35.44%
|
$669,736
$2.06 P/Share
|
|
Oct 01
2021
|
Marten Steen Director |
SELL
Payment of exercise price or tax liability
|
Indirect |
17,763
-21.68%
|
$35,526
$2.06 P/Share
|
|
Oct 01
2021
|
Fredric J. Cohen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
51,548
-24.32%
|
$103,096
$2.06 P/Share
|
|
Oct 01
2021
|
Richard S Kollender President and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
64,791
-21.67%
|
$129,582
$2.06 P/Share
|
|
Oct 01
2021
|
Stephen J Long Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
49,307
-29.51%
|
$98,614
$2.06 P/Share
|
|
Oct 01
2021
|
Scott L. Wilhoit Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27,515
-20.08%
|
$55,030
$2.06 P/Share
|
|
Sep 03
2021
|
Richard S Kollender President and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,088
-5.41%
|
$34,176
$2.24 P/Share
|
|
Jul 02
2021
|
John Johnson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
50,867
-5.11%
|
$152,601
$3.08 P/Share
|
|
May 18
2021
|
David N Gill Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+29.45%
|
-
|
|
May 18
2021
|
Garheng Kong Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+32.85%
|
-
|
|
May 18
2021
|
Jeffrey W Sherman Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+32.78%
|
-
|
|
May 18
2021
|
Marten Steen Director |
BUY
Grant, award, or other acquisition
|
Indirect |
40,000
+32.81%
|
-
|
|
May 18
2021
|
Hilde H Steineger Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+32.78%
|
-
|
|
May 17
2021
|
Richard S Kollender President and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,392
-3.48%
|
$22,784
$2.28 P/Share
|
|
May 14
2021
|
Marten Steen Director |
SELL
Payment of exercise price or tax liability
|
Indirect |
19,004
-31.2%
|
$38,008
$2.35 P/Share
|
|
May 14
2021
|
David N Gill Director |
SELL
Payment of exercise price or tax liability
|
Direct |
19,075
-25.47%
|
$38,150
$2.35 P/Share
|
|
May 14
2021
|
Jeffrey W Sherman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
18,944
-31.07%
|
$37,888
$2.35 P/Share
|
|
May 14
2021
|
Hilde H Steineger Director |
SELL
Payment of exercise price or tax liability
|
Direct |
18,944
-31.07%
|
$37,888
$2.35 P/Share
|
|
May 14
2021
|
Garheng Kong Director |
SELL
Payment of exercise price or tax liability
|
Direct |
19,200
-31.5%
|
$38,400
$2.35 P/Share
|
|
Apr 08
2021
|
John Johnson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,325
-1.71%
|
$34,650
$2.68 P/Share
|
|
Mar 03
2021
|
Richard S Kollender President and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+19.63%
|
-
|
|
Feb 22
2021
|
Fredric J. Cohen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,978
-3.19%
|
$20,934
$3.62 P/Share
|
|
Feb 22
2021
|
Stephen J Long Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,062
-4.05%
|
$21,186
$3.62 P/Share
|
|
Feb 22
2021
|
Robert Matthew Lutz Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,978
-3.71%
|
$20,934
$3.62 P/Share
|
|
Feb 22
2021
|
Scott L. Wilhoit Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,121
-4.94%
|
$21,363
$3.62 P/Share
|
|
Jan 07
2021
|
John Johnson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
491,000
+32.64%
|
-
|
|
Jan 07
2021
|
Fredric J. Cohen Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
181,000
+45.26%
|
-
|
|
Jan 07
2021
|
Richard S Kollender President and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
147,500
+37.34%
|
-
|
|
Jan 07
2021
|
Stephen J Long Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
143,500
+45.17%
|
-
|
|
Jan 07
2021
|
Robert Matthew Lutz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
147,500
+43.92%
|
-
|
|
Jan 07
2021
|
Scott L. Wilhoit Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
113,000
+43.94%
|
-
|
|
Sep 18
2020
|
Cdk Associates, L.L.C. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
6,000
+0.07%
|
$12,000
$2.2 P/Share
|
|
Sep 17
2020
|
Cdk Associates, L.L.C. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,473,377
+15.46%
|
$2,946,754
$2.25 P/Share
|
|
Dec 27
2018
|
Cdk Associates, L.L.C. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
18,200
+0.28%
|
$54,600
$3.98 P/Share
|
|
Dec 26
2018
|
Cdk Associates, L.L.C. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
31,197
+0.47%
|
$124,788
$4.0 P/Share
|